Invention Grant
- Patent Title: Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
-
Application No.: US15780620Application Date: 2016-12-02
-
Publication No.: US10709692B2Publication Date: 2020-07-14
- Inventor: Giorgio Bonanomi , Anthony A. Estrada , Jianwen A. Feng , Brian Fox , Colin Philip Leslie , Joseph P. Lyssikatos , Carmela Napolitano , Alfonso Pozzan , Anantha Sudhakar , Zachary K. Sweeney , Federica Tonelli , Javier de Vicente Fidalgo
- Applicant: Denali Therapeutics Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Denali Therapeutics Inc.
- Current Assignee: Denali Therapeutics Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: McNeill Baur PLLC
- International Application: PCT/US2016/064818 WO 20161202
- International Announcement: WO2017/096301 WO 20170608
- Main IPC: A61K31/422
- IPC: A61K31/422 ; C07D413/04 ; C07D261/02 ; A61P1/00 ; A61P29/00 ; A61K31/4439
Abstract:
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
Public/Granted literature
- US20180353480A1 ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) Public/Granted day:2018-12-13
Information query
IPC分类:
